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Introduction
Approximately one-third of the global population lacks access to life-saving
medicines, with nearly 100 million people pushed into extreme poverty
seeking treatment (Roth et al., 2018; Hazel, 2021). The cost of essential
medicines markedly contributes to the life-threatening gaps in accessibility
between the Global North and Global South (Hazel, 2021, Grover et al.,
2012). Meanwhile, the research-based pharmaceutical sector is one of the
most profitable markets in the world. Global pharmaceutical sales were $768
billion in 2016 and are expected to reach $1.5 trillion by 2023 (Hazel, 2021).
Most medical research in the US is conducted at universities with public
funding. University licensing agreements with pharmaceutical companies
can play a fundamental role in monopolies and price-gouging, rendering
medicines unaffordable. It is imperative that these research institutions
prioritize the public health benefits of medical innovation over financial
profits to ensure medicines are accessible to global citizens (Hoen, 2003).
We are part of a team of students representing the Case Western Reserve
University (CWRU) Partners In Health Engage (PIHE) and Universities
Allied for Essential Medicines (UAEM) who have been leading collaborations with the CWRU Technology Transfer Office (TTO) to ensure that
1 The authors are thankful for the support from other CWRU Partners In Health Engage
(PIHE) members who helped research and develop the Essential Medicines Equity
Framework for the CWRU Technology Transfer Office (TTO), which was made possible
with research from the Report Card Project developed by Universities Allied for Essential
Medicines (UAEM). The authors are especially grateful for help from Sarah Mathew and
Avaneesh Thoudoju for their efforts, research, and writing contributions in the sections
entitled Global Implications of Licensing and Moral Duties and a Call to Action for All
Global North Institutions, respectively. The authors thank Clara Harb for her significant
help in the final review and editing process. The authors are further appreciative of Johana
Canari, Lauren Roming, Sarah Zigo, Stephanie Sipics, Tram Phan, and Amber Akhter
for their contributions to our work with CWRU’s TTO and developing the Essential
Medicines Equity Framework for the CWRU TTO, and all the members of the CWRU
community and outside affiliates who reviewed and provided feedback on the Framework.
82

Jordan Reif and Chung   Ethical Obligation for Research Universities

83

licensing standards are equitable. Categorized as an “R1: Doctoral University” under the Carnegie Basic Classification framework, CWRU is among
institutions of higher education holding the highest level of recognition for
having “very high research activity” and “at least $5 million in total research
expenditures” (Basic Classification Description). As students in medicine,
bioethics, biology, and public health at a major research university in the
Global North, we believe there is an ethical obligation to both advance
the development of biomedical technologies and to ensure these life-saving
research products become universally accessible and affordable.
In this paper, we utilize an interdisciplinary approach to understand how
history contextualizes our current reality, the importance of lived experiences, and our ethical obligation to adopt the policy recommendations and
practices outlined in this paper in order to improve health outcomes locally
and globally. We will (1) review a brief history of global health; (2) argue
for the ethical duty for institutions to adopt equitable licensing standards;
(3) standardize a framework for utilization across research universities;
and (4) demonstrate the global health implications of improving access to
essential medicines.

Historical Background on Global Health
For centuries, global healthcare was considered a product of missionary
and colonial medicine through the lens of Christianity. Protestant tradition
sent physicians to the “New World”—land that was illegally stolen from
over 100 million indigenous populations through settler colonialism—to
open dispensaries and tend to the poor. These efforts were also extended
to the Caribbean and China (Grundmann, 1990). This general history
overlooks that independent health centers were the norm in the Middle
East and parts of Latin America centuries before the 1700s because, as
Haitian anthropologist Michel-Rolph Trouillot detailed, “history is the
fruit of power,” as told by the winners, the colonizers (Trouillot, 1995). We
think this brief, albeit insufficient, history of missionary health is central
to understanding global health injustice today, especially the lack of robust
healthcare infrastructure.
Missionary health was intimately intertwined with international health
efforts to control epidemics across countries in the 19th–20th centuries
(Brown et al., 2006). Global health initiatives, considering the health of
people rather than borders, developed later in the 20th century. Increased
globalization (social, economic, and political interdependence) facilitates
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the dissemination of technologies (contraception, communication, and
potable water), human rights standards, infectious disease, conflict, and
other threats which exacerbate poverty (Yach & Bettcher, 1998).
Globalization impacted the way international health and global health
were conceptualized and operationalized. The transition from international to global health promoted a shift to frame health in terms of equity
(Beaglehole & Bonita, 2010). Partners In Health—and its founders, Paul
Farmer, Jim Yong Kim, Ophelia Dahl, and other colleagues—work(ed)
tirelessly to decolonize global health from its imperial roots in favor of a
biosocial approach that incorporates medicine with anthropology, sociology, history, ethics, and political economy (Farmer et al., 2013). In doing
so, global health’s powerful role in disease mitigation shifted toward social
justice to recognize the role of power in illness and health.
Pharmacology and science are required to develop and manufacture medications but play a lesser role to power and profit in terms of accessing biomedical technology and medicines. We can turn to bioethics to understand our
obligation to improve universal access to essential medicines. As we are all
based in the United States, our obligations refer to those of the Global North
where advanced biomedical research and exclusive licensing are rampant.

Long-Standing Issues in Access Viewed through the Lens of
Bioethics
In the 1960s–70s, hemodialysis, mechanical ventilation, artificial nutrition, and other biomedical innovations were discovered to prolong human
life. Medical teams were tasked with deciding who had access and how much
life-sustaining treatment was ethical. Simultaneously, journalists published
accounts of unethical research, including the Tuskegee Syphilis Study and
the Stanford Prison Experiment. Together, these factors formalized a new
discipline, bioethics, to answer questions about life and death and to better
operationalize the Hippocratic Oath’s demand to do no harm (Jonsen, 1991).
In 1979, Tom Beauchamp and James Childress developed principles
for biomedical ethics to help dissect ethical issues in medicine, including
autonomy, beneficence, non-maleficence, and justice. Autonomy states that
people who have agency and liberty ought to be able to make their own
medical decisions. Beneficence is the obligation for healthcare workers to
do good by their patients by acting in their best interest. Non-maleficence
requires that practitioners avoid harm to their patients. Justice considers how
benefits and burdens are distributed to a population.
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These principles have served as a guiding model for determining standards
for animal research and drug trials, monitored by the US government,
thereby setting a precedent for government intervention to ensure safety
and equity through the development process of new biomedical technologies (Menikoff et al., 2017). All four principles, most notably justice, can be
applied to our concerns about exclusive licensing and patents for essential
medicines. First, by our evaluation, “essential” medicines—including insulin, chemotherapy, immunotherapy, antiretroviral therapy, and tuberculosis regimens, among others—provide extended quality years of life. If a
medicine is offered to a patient with the best American health insurance,
it ought to be considered essential.
As the field of bioethics emerged, philosopher John Rawls introduced a
concept on what he called the “Veil of Ignorance.” This thought experiment
compels an individual to consider what social support they would want
provided if they did not know their class, race, ethnicity, gender, religion,
and so forth (Rawls, 1971). Scholars agree that the Veil of Ignorance indicates countries have an obligation to ensure positive rights—to provide
essential healthcare (Korobkin, 1998; Fritz and Cox, 2019). Using Rawls’
framework, there is a clear beneficent and non-maleficent obligation for
people with power to prioritize the provision of fundamental human rights.
Nativism, racism, and neoliberalism prevent solidarity-based approaches
in favor of individualism. Yet, for centuries, societies founded their policies
on the idea of providing the best outcome for most of their population.
Most countries in the Global North countries, with the exception of the
US, have a national healthcare system because they value the principles
of access, justice, and accountability. In the US, individual autonomy is
prioritized over social justice and collective well-being. However, people
cannot act autonomously without access to all available options. The liberty
component of autonomy is restricted because there is no “independence
from controlling influences” (Beauchamp & Childress, 2019). Inadequate
power and resources control the decision. By limiting access to life-saving
treatments, we are stripping autonomy from millions of people, thus making
our protection of the principle inconsequential. We can adopt a consequentialist approach—similar to the justification for national health systems in
other countries—to prioritize equitable access to essential medicines over
the profits of a few politicians, high-level executives, and shareholders.
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Justice Considerations for Global Health Authorities Beyond
Universities
With over 450 million cases, including six million deaths worldwide,
the response to COVID-19 has been a race of unprecedented speed and
unrelenting international research efforts to transition this disease from
life-threatening to vaccine-preventable. Although the World Health Organization (WHO) announced that countries representing 64% of the world’s
population made legally binding commitments to buy and fairly distribute
COVID-19 vaccines globally, we have still seen a vaccine apartheid unfold
with a surplus of vaccines in the Global North and an insufficient number
in the Global South. World leaders have failed to facilitate the equitable
distribution and access to publicly funded, life-saving vaccines, ultimately
forgoing justice in times of a pandemic and revealing an unacceptably high
level of moral negligence.
In order to protect individuals and communities from emerging health
threats, world leaders must develop protective measures and procedures
taken by state and local health authorities that are ethical, legal, and effective.
The devastating consequences on individuals, families, and communities
due to weak infectious disease infrastructure cannot be ignored any longer
(Lagay, 2004; Margolis, 2001). While outbreaks are sometimes unpreventable, the danger becomes far greater when they are left uncontrolled and
unmanaged (CDC, 2015). Failure to “meet the minimum capabilities . . . for
readiness” can cause health hazards from emerging infectious diseases
to become epidemics, or even pandemics, resulting in unnecessary and
largely preventable deaths, especially for those from our most vulnerable
communities (Mayer, 2009).
All people are susceptible to contracting COVID-19, but that does not
mean the disease is non-discriminatory. The pandemic has highlighted that
individuals with a low socioeconomic status (SES) experience a disproportionate burden of disease since they have restricted access to medical care.
Despite the economic growth of the last century, the global distribution of
wealth remains intentionally unbalanced due to many systemic injustices
including colonialism (now neo-colonialism), through which continued
resource and labor exploitation are rampant, widening gaps in access to
healthcare, education, potable water, healthy and affordable food options,
and sanitary environments ( Jones, 2010). Lack of access to other essential
supplies increases transmission and mortality risk for COVID-19 among
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other diseases and pathological conditions that have their own unique
comorbidities (Beauchamp & Childress, 2012).
Moreover, low SES is deeply intertwined with race, ethnicity, education level, citizenship status, and immigration status because societies have
been built on the exploitation of the minority groups which experience
these covariates most often. Populations at high risk for COVID-19 exposure and mortality have been forced to endure the systemic injustices that
actively work to oppress racial and ethnic minority groups. This oppression
includes “long-standing racial bias in health care—including the dismissal
of legitimate concerns and symptoms—that can help explain poor [health]
outcomes even in the case of black [people] with the most advantages”
(Villarosa, 2018).
Although COVID-19 has helped shed light on the “deep fault-lines in
our medical system . . . that stratify health care along lines of race, class,
age, and disability,” properly combating public health threats aggravated
by systemic injustice necessitates significant mobilization of resources and
international cooperation (Ginsburg et al., 2020). These collaborations
can help ensure equitable and ethical medical resource distribution for the
people who are the most urgently at risk for infection and death with more
limited access to treatment or safety measures. Marginalized people have
a right to high-quality healthcare, and under-prioritizing them during a
global pandemic is a serious threat to their chance of survival (Beauchamp
& Childress, 2012).
Therefore, as demonstrated most recently by this pandemic, our world’s
primary justice consideration must first and foremost speak to protecting
the most vulnerable lives from the most disadvantaged nations. Global
leaders must adopt a sense of duty and moral obligation to combat the
disproportionate burden of disease and death by implementing legislative
policies that would improve access to and affordability of medicines for
populations who face vulnerability, exploitation, and discrimination.
When health disparities and issues of justice get overlooked or dismissed
by the very leaders who claim to be advocates of health equity and social
justice, then the goal of providing equitable access to life-saving vaccines
and other essential medicines cannot be achieved. Although neoliberalism
and contemporary ideas associated with free-market capitalism have made
efforts to support vulnerable populations unpopular, now is the time to
set a precedent of solidarity and stand firm in our obligation to protect the
lives that have, for so long, been forgotten and left behind.
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Biomedical Licensing and Barriers to Optimal Health in the US
In the US, nearly one in four people cannot afford healthcare, despite
the fact that this country is home to many hubs of pharmaceutical development (Kaiser Family Foundation, 2019). Access is worse in the Global
South due to people facing physical inaccessibility to medications as well as
generally lower incomes. As reviewed in our brief history of global health
delivery, lack of access to medicines is a consequence of colonialism due
to inadequate and unsustainable healthcare infrastructure (Kettler et al.,
2020; Bigdeli et al., 2013).
Without investment in “stuff, staff, space, and systems”—as promoted
by the founders of Partners In Health—many low-income people rely on
informal paths to access healthcare resources (Mills et al., 2002; Building
Strong Health Systems, 2021). Of all healthcare costs, medicines account
for 20–60% of health spending in low- and middle-income countries, with
50-90% of these expenses being billed as out-of-pocket costs, placing an
undue burden on already vulnerable populations (Cameron et al., 2009;
WHO, 2004; Bigdeli et al., 2013). In Table I, we frame how the cost of
medicines affects all five levels of health systems (Bigdeli et al., 2013).
These barriers essentially serve to impact the way medicines are licensed
and patented, thereby either promoting or restricting access.
There are a host of mechanisms, detailed in an investigation by the US
Congressional Research Service, that pharmaceutical companies and institutions use to increase profit, limit competition, and extend monopolies (Richards et al., 2020). Pharmaceutical patents, a form of exclusive licensing for
innovation and production, are typically awarded in the US for twenty years
from the date of patent filing, and similar licensing policies exist throughout
the Global North. Through the 1980 Bayh-Dole Act, American universities
gained financial incentives to commercialize innovation and support pharmaceutical profits (Ouellette & Tutt, 2020). Moreover, patent holders can
repackage old research products or make minor modifications (such as making
changes to the form or dosage) to perpetuate their patent when, in fact, it
did not require true innovation. This technique is known as “evergreening,”
a practice which not only increases prices, but also solidifies monopolies.
Manufacturers also promote “product hopping,” which is defined as removing an old product or introducing a new, but similar product as a new patent
with a later date, thus extending the exclusive licensing agreement. Repeated
“evergreening” and “product hopping” leads to “patent thickets,” thereby
limiting space for generics. Further, companies can negotiate “Pay-for-Delay’’
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agreements by offering settlements to other companies to delay releasing a
generic alternative. On average, there were 125 patent applications filed for
each of the top twelve grossing medications of 2017; approximately seventyone patents were successfully issued for each, blocking nearly forty years of
competition (Initiative for Medicines, Access, and Knowledge, 2020). No
statutes exist in the US to forbid these tactics and global initiatives spearheaded
by non-governmental organizations lack enforcement.
Table I
Barriers to accessing medicines categorized by health system level.
Extrapolated from Bigdeli et al. article and table on strengths and weaknesses of existing frameworks
(2012).

Level of health system

Barriers to accessing medicines

Individual, household and
community

Cost of medicines and services

Health service delivery

High medicine prices
Irrational prescription and dispensing

Health sector

Pharmaceutical sector governance
Medicines price control

Public policies cutting across
sectors

Low public accountability and transparency
Low priority attached to social sectors
Conflict between trade and economic goals
for pharmaceutical markets and public health
goals

International and regional level

Unethical use of patents and intellectual
property rights
Distorted research and development, not
targeting disease burden in low- and middleincome countries

Another practice, previously invisible to many people across the world, is
the effect of licensing on access to COVID-19 vaccines compounded with
the implications of institutionalized racism. In October 2021, Moderna
Therapeutics refused to share their vaccine recipe; in response, the WHO
hired a biotechnical company in South Africa to reverse engineer it (Aizenman, 2021; Maxmen, 2022). The South African company succeeded in
replicating the vaccine in February 2022, paving the way for increased vaccination rates on the continent (Maxmen, 2022). While Moderna agreed to
not enforce intellectual property rights—at least during the pandemic—by
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refusing to disclose the vaccine’s ingredients, the company is prioritizing
their profits over the health and well-being of people during a public health
emergency, further inflating global transmission and mortality rates.
To further expand on the context and consequences of these actions, it
is essential to note that in 2019, Moderna’s revenue was $60 million, and in
2021, they were projected to generate at least $20 billion (Robbins, 2021).
Additionally, from a comparative perspective, while the United Kingdom
had succeeded in vaccinating 85% of its population by December 2021,
only 6% of the continent of Africa had completed a full, two-dose vaccine
regimen (Ivanova, 2021). This reality is known as a vaccine apartheid because
it communicates how the disparity is a direct result of intentional decisions
around power, profit, and medicinal access.
In addition to making biomedical licensing more equitable, efforts must
be made to implement large social investments, such as appropriate financial
reparations, which work to address centuries of colonization and oppression. For example, in a study done by medical anthropologists comparing
COVID-19 transmission rates in Louisiana and South Korea, researchers
found that if descendants of enslaved people in the US had been recipients
of financial reparations in the years prior to the COVID-19 pandemic,
transmission rates in Louisiana could have been 31–68% lower (Richardson,
et al., 2021). Reparations can help develop generational wealth, which
ultimately allows people to experience greater opportunities for access to
healthcare. Social investments, outside of improving biomedical licensing,
are crucial to both acknowledging historical violations of human rights
and directly seeking to improve quality of life.

Global Health Implications of Licensing
The urgency of addressing licensing issues cannot be separated from
their global health implications. Therefore, it is important to discuss the
threats to public health and well-being when we fail to take these negative
tradeoffs into consideration, highlighted by current issues with the prescription medications Xtandi, Daraprim, dt4, and the recently developed
COVID-19 vaccine.
Xtandi is a treatment for late-stage prostate cancer that was developed
at the University of California Los Angeles (UCLA) in the early 2000s.
Although Xtandi is the only medication available to the 1.5 million people
diagnosed with prostate cancer in India, it is priced at over forty times
the average per capita income, making it inaccessible to those who need
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it most. UCLA sold its royalty interests to Royalty Pharmaceuticals and
Japanese-based pharmaceutical company, Astellas (Hampton, 2016). The
university then filed a patent claim on its ~43% royalty share which was
denied by the Indian Patent Office (Mukherjee, 2016). Mumbai-based
BDR Pharma produced an affordable alternative, threatening the profits
of Xtandi, leading UCLA to appeal the patent denial to the high court.
UCLA must be held accountable by accepting profit cuts and increasing
the accessibility of Xtandi to millions. Their goals, which revolve around
leadership in research, grants, and patents, are incompatible with their
current practice of prioritizing profit over the lives of people with prostate cancer (Stout et al., 2018). Additionally, large, networked institutions
like UCLA set the precedent for patent royalties in partnerships, given
that nearly 25% of the 252 medications approved by the Food and Drug
Administration (FDA) between 1998 and 2007 were initially developed at
universities (Panditrao & Aditi Mridul, 2017).
Pharmaceutical lobbyists in the US Congress also play a major role in
limiting biomedical licensing regulation. Turing Pharmaceuticals CEO,
Martin Shkreli, increased the price of Daraprim, an HIV medication, by
5000% overnight and hired lobbyists to combat the congressional outreach
and public outcry against drug pricing alterations that ensued. The pharmaceutical industry heavily fortifies federal lobbying in Congress (including $300 million in campaign donations) to ensure medicine costs do not
decrease, even with major insurance reforms like the Affordable Care Act
(CREW, 2018; Geubert & Bubela, 2014).
Profit-seeking behaviors are preventing people around the world from
receiving healthcare and life-saving therapies. In South Africa, the country
with the highest number of new HIV/AIDS infections annually, pharmaceutical profits are prioritized over the health of millions (Laher et al.,
2020). Despite the incidence of the disease, less than 1% of the HIV positive
population in SA receive proper care due to overwhelming financial barriers. In the 1980s, Yale University developed the antiretroviral medication,
d4T, and negotiated a patent agreement with Bristol-Myers Squibb (BMS)
that would have resulted in a high cost barrier once this product hit the
market (Borger & Boseley, 2001). However, due to pressure from negative
media attention organized by student advocates, Yale-BMS decreased the
cost of d4T in SA to 1/34th of its original price (Post, 2003).
In Latin America, Pfizer Pharmaceutical, which was providing vaccines
to the region, demanded that Brazil and Argentina put up assets such as
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military bases as collateral to cover any legal fees Pfizer could incur from
civil suits or negligence accusations during vaccine dissemination (Davies,
2021). Similar abuse of power exists in Colombia, where the government
paid $27–30 per dose for Moderna vaccines while the US paid $15–16 per
dose (Robbins, 2021). These events, among others, culminated in government officials releasing statements expressing how they felt as though they
were being “held for ransom” for daring to gain access to life-saving vaccines
for their populations (Davies, 2021). Soon thereafter, Pfizer announced
that they would collaborate with a Brazilian pharmaceutical company to
manufacture vaccines for the region (Pfizer, 2021).
Even though this action is a step in the right direction, Pfizer’s decision to help manufacture more vaccines in the region was likely an effort
to escape negative press, thereby reaffirming their power in this twisted
dynamic. It is these systemic, intentional decisions made by manufacturers
without accountability that cause and perpetuate vaccine apartheid and
other instances of global health injustice.

Collaborating with TTOs to Improve Licensing Standards
Renowned research institutions maintain a high magnitude of innovation
and experimental processes required to further research and development.
Since the 1970s, the Carnegie Classification of Institutions has categorized
universities based on degrees awarded and research expenditure (Basic
Classification Description). R1 (very high research activity) and R2 (high
research activity) schools are doctoral universities which award at least 20
doctoral degrees in a given year and receive at least $5 million in total
research expenditure as reported by the National Science Foundations
(Basic Classification Description).
These schools have the stuff, staff, space, and systems to conduct highlevel biomedical research with the potential to treat and cure disease and
disability. As such, R1 and R2 institutions must lead equitable framing
initiatives. These schools have the most interaction with pharmaceutical
and manufacturing companies and, thus, the most power to improve access.
The licensing standards and contracts negotiated with pharmaceutical
companies are what ultimately determine pricing, length of monopoly, and
competition. We will review how currently intellectual property standards
threaten essential medicine access and how constituents of R1 and R2
universities can collaborate with technology transfer offices to improve
licensing standards.
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Innovation, as intellectual property (IP), is often patented so that it can
be protected. However, protecting IP over access to necessary health care
is antithesis to the stated values of most R1 and R2 schools. Universities
are guided by pillars of engagement, integrity, and stewardship, seeking
to improve the lives of people around the world. However, their actions
within the realm of biomedical advances may not always reflect this sentiment. By not taking aggressive, intentional action to improve biomedical
licensing, universities are falling short of the goals and commitments they
have outlined in their missions.
Due to the substantial role of universities in developing biomedical
technology, managing IP responsibly can improve access to medical innovations globally (Hoen, 2003). Moreover, most of this research is funded by
American taxes through National Institute of Health (NIH) grants. NIH
funding has contributed to every medication—210 in total—approved by
the FDA between 2010-2016 (Cleary, et al., 2018; Mamidi, 2021). Yet,
there is not widespread access to medicines, nor does the US believe there
ought to be universal healthcare, distinguishing itself from the rest of the
world with its fatal individualism complex.
A university’s groundbreaking research can only enrich and improve
people’s lives insofar as it is affordable and accessible to those who need
it. Concerned that our university was not fulfilling its obligation to make
technology accessible, we organized meetings with the TTO to develop a
greater understanding of how the office makes negotiations with manufacturing companies and secures licensing agreements for research products
made at the university. As students, we felt an obligation to (1) understand
our own university’s policies and practices as it relates to limited access and
(2) advocate that we promote justice and universal access to healthcare.
Figure I outlines our general process for engaging with university TTOs
and recommending licensing improvements.
During the initial meetings with TTOs, student leadership groups will
focus on acquiring a stronger understanding of the office’s main goals,
interests, and hesitations with biomedical licensing. After engaging in these
conversations and establishing a relationship with the TTO, students can
work on outlining their main concerns surrounding any lack of transparency
in the licensing process, insufficient exploration and use of non-exclusive
licensing alternatives, and inadequate oversight on manufacturing companies
with whom we have agreements.
Given the precedent of exclusive licensing as the standard for awarding
innovation, many TTOs may have the misguided belief that, without
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Figure I. Overview of the process used to engage with TTOs at research
institutions.
patents, we would not have biomedical technology advancement. Conversations with TTOs should also determine the level of support and interest in
changing the licensing status quo. Offices may verbally acknowledge equity
as an important consideration, but delay or refuse adoption of alternative
licensing practices. TTOs, at the minimum, should be receptive to meeting with university students and being transparent about their licensing
standards. Excellent TTOs will consider recommendations from students
and alter policies for maximum transparency and accountability. Figure
II indicates common discourses of delay that TTOs will use to limit or
prolong licensing changes.
Prior to, and throughout meetings with TTOs, students will need to be
responsible for conducting their own independent research on licensing policies. UAEM produces report cards outlining positive actions and areas for
improvement for leading American research universities. They also author
the UAEM Evidence Wordpress blog to collate information and evidence
in support for alternatives to exclusive licensing (UAEM Evidence). We
heavily relied on this research and interdisciplinary discussions with other
health organizers around the country.
Based on our experience working with TTOs, we developed a framework
explaining the biomedical licensing process and areas for improvement.
We highly recommend this approach for other institutions, as it can help
educate the university, raise awareness, outline university accomplishments
and areas of concern, and list institution-specific action items to improve
access. We have included general categories related to licensing and sample
action steps and practices that R1 and R2 institutions would be able to
adopt if they are truly committed to addressing the outstanding issues that
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shape and are shaped by access to biomedical innovations (Table II). These
policies and guidelines were developed using the UAEM report card grades
which rate research institutions’ commitment to transparency, equitable
licensing, research for neglected health needs, and student empowerment.
Table II
Policy recommendations and action items for R1 and R2 universities. These can be adapted to be university-specific and incorporated into a framework presented to the technology transfer office.The items
should be prioritized and include expected timelines and measures for accountability.

General Policy
Recommendations

Specific Action Steps and Practices

Publicly support
UAEM’s Equitable
Technology Access
Framework

Waive market and data exclusivities when at all possible.
This includes abstaining from applying for extensions
on market and data protections. Promotion of these
exclusivities can often block or delay competition and
thus increase monopolies and cost. The Food and Drug
Administration permits up to 5 years of exclusivity for
most small molecules that have not previously been
approved. This length should never be exceeded, unless by
the discovery of a drug to treat an orphan condition (fewer
than 200,000 individuals in the US), at which 7 years of
exclusivity is permitted (Hennebry, 2018).
Increased transparency about meetings with manufacturers
and pharmaceutical companies. Notes should be taken
during these meetings to record concerns and agreements.
Notes should be made available.
All (most likely, but not limited to, federal) funding
sources and amounts should be disclosed in annual reports
and made available online. This includes the amount
of funding for the research and development process
with markers indicating the use of the funds. Given the
necessity of grant proposals, researchers should be able to
easily compile an itemized list of funding.
Include step-in rights: Universities should be able
to intervene and alter or end the agreement with a
manufacturer if they are not meeting the obligations of the
agreement. This can ensure higher equity standards are
included and being met.

Publicly support at
least one COVID19 open technology
framework

• Open COVID Pledge (OCP)
• Coronavirus Technology Access Pool (C-TAP)
• S tanford/Harvard/MIT COVID-19 Technology Access
Framework
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Specific Action Steps and Practices
More disclosure about the processes, funding, goals, and
outcomes within the technology transfer office. A public
website should include more information about how
commercialization of university intellectual property is
conducted and approved.
Answers to the following questions are a start to outline
the technology transfer process:
•H
 ow does the office seek out manufacturers and
pharmaceutical companies to license technology to?
• W hat, if any, standards are set for these companies?
•H
 ow does the university decide whether licensing will
be pursued for an innovation or product?
•H
 ow does the university decide with whom this
licensing agreement will be made?
•H
 ow does the university monitor compliance with the
licensing agreement?
•W
 hat decisions by manufacturers and pharmaceutical
companies will not be tolerated?
•W
 hen is information shared with the university/public
about licensing agreements?
•D
 oes the amount of public money invested in the
product impact licensing decisions?
•W
 hat amount of transparency is required from
manufacturers and pharmaceutical companies?

Include people
outside the
technology transfer
office in licensing
negotiations

The technology transfer office should include at least one
undergraduate and two graduate students (if possible,
one from medical school and one from law school) in the
licensing review process. These students will be able to
raise concerns about the equity of an agreement and their
opinions should hold equal power.

Ensure
accountability and
regular follow-up
meetings

The technology transfer office should seek out, agree to,
and continue collaborations with students and interested
entities. This should include, at least, 3 meetings per
year to review updates. The university should mandate
reporting for all clinical trial results and funding.
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General Policy
Recommendations

Specific Action Steps and Practices

Ensure obligations
are met of current
agreement, if
applicable. Many R1
and R2 universities
have agreed to a
UAEM Global Access
Licensing Framework.

Legally prevent manufacturers and pharmaceutical
companies from engaging in tactics that can block generic
competition, especially for production in resource-limited
countries. The following should not be permitted:
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•F
 ollow-on patents, including product, process, and
use patents. These types of patents promote multiple
licensing agreements for incremental developments.
Other provisions can be included into agreements to
promote equity and competition. The following should be
included:
•A
 t-cost provisions: Licensed technology should be
made available for no profit when: (1) “[a] component
of the licensed product is too complex to be feasible
for replication and generic production;” and/or (2)
“the demand for the product . . . is too small to induce
a generic company to enter the production” (UAEM
2010).
“Do not seek patents on research platforms, diagnostic
tests, and other technologies that can be adapted for
commercial use in a short period with little additional
investment.” (UAEM 2010).
•P
 atent on these types of inventions hinder innovation
by adding costly licensing fees and can promote patent
thickets

Actively promoting
equitable licensing

For all patents, rely on non-exclusive licensing. All rights
to the products should be reserved by the university. The
product should be shared widely to encourage competition
(UAEM 2010).
Review pending and future license agreements—including
students—to limit all exclusive licensing agreements.
Collaborate with other universities (public and private) to
learn best methods for prioritizing non-exclusive licensing,
including communication with manufacturers and
pharmaceutical companies.

Moral Duties and a Call to Action for All Global North
Institutions
We call on R1 and R2 universities to share our process and framework
to educate other members of the institution on the urgency and implications
of licensing decisions and to pressure administrators to transition away from
grandstanding and profit-driven decisions toward real accountability. We

98

The International Journal of Ethical Leadership    Summer 2022  

Figure II. Common discourses of delay from TTOs and universities who are
hesitant to transition away from exclusive licensing standards. Adapted from Lamb
et al. article and figure on discourses of climate delay (2020).
urge these biomedical research institutions in the Global North to adopt
alternatives to exclusive agreements, such as open-source listing, which
makes details of innovation freely available to others in academia and the
broader public. In addition to promoting competition, open-source listing
also prevents others from patenting the invention, which helps to protect
the institution’s innovative achievement while also increasing accessibility
to a potentially life-saving product.
University research is upstream from the development process. Using an
open-source listing model means that there is a chance for early leverage,
with blind foresight to predict marketability. In order to effectively fight
against limited accessibility to life-saving medicines, universities need to
acknowledge that research is intended to meet public needs, including
health care advancements. As such, global public health concerns should
be considered in the patenting and licensing process.
Research universities across the Global North need to reassess their role
in promoting or preventing accessible medicines worldwide. Developing
biomedical technology is one small part of improving healthcare. Universities are responsible for leading conscious efforts to limit exclusive agreements
and make ethical decisions about licensing. While equitable licensing is
a clear mechanism for universities to promote global health justice and
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to hold pharmaceutical companies more accountable, these actions must
be adopted in tandem with other efforts which seek to strengthen health
systems while also addressing discrimination globally.
Ultimately, the benefits of such an approach can be demonstrated by the
events of the COVID-19 pandemic detailed in the Justice Considerations
for Global Health Authorities section above. Therefore, in addition to committing to more equitable licensing standards, universities must improve
transparency about the process and strive to educate researchers, students,
and other members of the institution on the gravity of licensing decisions
within the context of global health access.

Conclusion
Global health justice will only advance through collaborations between
organizations, disease control authorities, health departments, and ministries of health. These health advocates and leaders must address preventive
health practices, infectious disease treatment goals, obstacles to accessing
healthcare, and disparities in health outcomes with the knowledge that
integrative approaches to healthcare build stronger, more sustainable health
infrastructures, and prepare systems for crises.
Together, with community input, these groups can enact effective strategies, address health disparities, offer constructive feedback, and expand
support systems. However, when health authorities at the university and
global levels fail to prioritize justice and access in their policy decisions
and innovation licensing, individuals and populations die from preventable
and treatable conditions. Academic biomedical research institutions and
governmental bodies around the world must adopt the values of justice by
actively addressing the gaps in essential medicine access and affordability.
We recognize that research universities, especially those designated
as R1 (very high research activity) and R2 (high research activity), are a
small part of a larger system designed for the Global North to profit off the
exploitation of the Global South. We hope our framework demonstrates
the tangible actions that biomedical institutions must take to fulfill their
obligation to the world. These obligations extend past perfunctory pledges
and value statements to genuine system-level change and robust mechanisms
of accountability. We believe that adopting these general guidelines and
specific action steps will provide practical implications for the betterment
of humankind. Universities can further use their connections to urge other
sectors to invest in global health justice.
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Leaders in bioethics, medicine, and public health are some of the loudest voices for change. We urge leaders across these and other disciplines
to join us in combating preventable morbidity and mortality, investing in
education around the urgency of social justice, and building resiliency to
continue the fight for justice. Through these developments we will help
our world move through this pandemic to a brighter future with accessible
healthcare, potable water, humane housing, fair labor laws, and sincere
dedication to addressing the climate crisis.
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